Deutsche Bank upgrades Colgate-Palmolive stock rating on growth strategy By Investing.com

Deutsche Bank upgraded Colgate-Palmolive to Buy and raised its price target to $98 from $90 while the stock trades at $84.29 (InvestingPro fair value $90.83). Colgate beat Q4 EPS at $0.95 vs $0.91 consensus, UBS reiterated Buy (PT $93) and Morgan Stanley raised its PT to $100; the company raised its quarterly dividend to $0.53 ($2.12 annualized). Management is realigning operating segments effective quarter ending March 31, 2026, and is pursuing premiumization, data/AI initiatives and other productivity investments, though DB cautions North American headwinds may appear in Q1 2026 before improving.

Analysis

The company sits at an operational inflection where premiumization and better demand-generation analytics can convert SKU-level pricing power into outsized operating leverage. If execution reduces below-the-line trade spend and shifts incremental sales toward higher-AUR SKUs, expect 150–300bps of operating-margin tailwinds over 12–24 months absent a simultaneous jump in input costs.

Competitive dynamics favor incumbents who can fund marketing and R&D while pulling mix forward; smaller peers and private labels will pressure volume but struggle to match innovation-led margin capture. Secondary beneficiaries include packaging and contract-manufacturing suppliers (who gain scale) and specialized analytics/AI vendors (who monetize improved data pipelines), while large grocers face compression if category margins normalize higher.

Near-term risk is macro-driven earnings noise: FX and energy swings can mask improving core trends and create headline misses that the market will punish within days. Key catalysts to watch over the next 3–18 months are the first prints following strategic realignment, emerging market organic-growth cadence, and any governance-driven strategic moves (portfolio carve-outs or bolt-on M&A) that crystallize value.

Tactically, optionality is preferable to outright long exposure until we see concrete signs of margin recovery — the path to upside is stepwise and event-driven. Position sizing should assume a binary Q1 outcome: favorable execution unlocks catch-up rerating in 6–12 months, adverse macro or private-label gains could erase a year of progress quickly.

Key Decisions for Investors

• Pair trade (6–12 months): Long CL / Short PG — equal-dollar exposure to capture relative upside from premiumization execution. Target relative outperformance of +15% (take profit) with a stop if CL underperforms by -10%. Size at 1–2% NAV net exposure and re-evaluate after next quarterly print.
• Call-spread (12–18 months): Buy a 12–18 month bullish call spread on CL to capture margin recovery with defined downside. Finance sale leg by selling nearer-term OTM calls; expect 2–4x payoff on premium if execution lifts multiple, maximum loss = premium paid (~2% of notional).
• Short idea (6–12 months): Short KMB (Kimberly‑Clark) small position to express lower optionality on premiumization vs peers — target 10–15% downside or relative underperformance versus CL/PG. Use a 6–9 month horizon and hedge market beta with an index ETF if volatility rises.
• Event hedge (days–weeks around print): If holding long exposure into the upcoming quarter, buy short-dated protective puts (2–6 weeks) sized to cap drawdown to ~10–12% while leaving upside uncapped. Cost is insurance — justified given binary reaction risk from FX/energy-driven headlines.